Australia markets closed

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
75.60+1.10 (+1.48%)
At close: 04:19PM BST
Currency in CHF

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.25
52-week change 319.44%
S&P500 52-week change 332.65%
52-week high 375.60
52-week low 333.75
50-day moving average 363.20
200-day moving average 348.12

Share statistics

Avg vol (3-month) 31.44k
Avg vol (10-day) 31.06k
Shares outstanding 515M
Implied shares outstanding 6N/A
Float 88.42M
% held by insiders 147.29%
% held by institutions 112.37%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 32.00
Trailing annual dividend yield 32.68%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 37.53%
Operating margin (ttm)63.83%

Management effectiveness

Return on assets (ttm)7.82%
Return on equity (ttm)14.80%

Income statement

Revenue (ttm)185.36M
Revenue per share (ttm)11.52
Quarterly revenue growth (yoy)212.00%
Gross profit (ttm)N/A
EBITDA 99.91M
Net income avi to common (ttm)69.57M
Diluted EPS (ttm)1.30
Quarterly earnings growth (yoy)5,013.80%

Balance sheet

Total cash (mrq)133.41M
Total cash per share (mrq)8.31
Total debt (mrq)1.46M
Total debt/equity (mrq)0.29%
Current ratio (mrq)4.85
Book value per share (mrq)31.06

Cash flow statement

Operating cash flow (ttm)117.33M
Levered free cash flow (ttm)72.86M